ALECTOR INC (ALEC) Stock Price, Forecast & Analysis
USA - NASDAQ:ALEC - US0144421072 - Common Stock
ALEC Key Statistics, Chart & Performance
The current stock price of ALEC is 1.44 USD. In the past month the price decreased by -54.72%. In the past year, price decreased by -74.96%.
ALEC Latest News, Press Relases and Analysis
ALEC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.43 | 374.44B | ||
| AMGN | AMGEN INC | 13.59 | 159.52B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.54 | 109.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.27 | 68.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.12 | 56.90B | ||
| ARGX | ARGENX SE - ADR | 61.62 | 50.87B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.04 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.99B | ||
| BIIB | BIOGEN INC | 9.05 | 22.20B |
Related stock screener links
About ALEC
Company Profile
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 163 full-time employees. The company went IPO on 2019-02-07. The firm is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. The company also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Company Info
ALECTOR INC
131 Oyster Point Blvd., Suite 600
South San Francisco CALIFORNIA 94080 US
CEO: Arnon Rosenthal
Employees: 163
Phone: 14152315660
ALECTOR INC / ALEC FAQ
What does ALECTOR INC do?
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 163 full-time employees. The company went IPO on 2019-02-07. The firm is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. The company also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
What is the current price of ALEC stock?
The current stock price of ALEC is 1.44 USD. The price decreased by -2.04% in the last trading session.
Does ALEC stock pay dividends?
ALEC does not pay a dividend.
What is the ChartMill rating of ALECTOR INC stock?
ALEC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the ex-dividend date for ALEC stock?
The next ex-dividend date for ALECTOR INC (ALEC) is November 4, 2022.
How many employees does ALECTOR INC have?
ALECTOR INC (ALEC) currently has 163 employees.
What is ALECTOR INC worth?
ALECTOR INC (ALEC) has a market capitalization of 145.74M USD. This makes ALEC a Micro Cap stock.
ALEC Technical Analysis
ALEC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALEC. Both the profitability and financial health of ALEC have multiple concerns.
ALEC Financial Highlights
Over the last trailing twelve months ALEC reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 35.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.35% | ||
| ROE | -161.98% | ||
| Debt/Equity | 0.13 |
ALEC Forecast & Estimates
15 analysts have analysed ALEC and the average price target is 2.24 USD. This implies a price increase of 55.83% is expected in the next year compared to the current price of 1.44.
For the next year, analysts expect an EPS growth of -29.37% and a revenue growth -74.24% for ALEC